logo-loader
NASDAQ:CLRB

Cellectar Biosciences

Receive alerts
Market:
NASDAQ
Market Cap:
$13.25 m
Price
1.41 USD
Change
-6.62%
52 weeks high
3.31
52 weeks low
1.05

In brief

Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar’s PDC platform is based on the company’s proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar’s PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging.